Study of ENN0403 for diabetic macular edema
Part of Eyes & vision clinical trials.
This trial tests a new eye drop or injection called ENN0403 for people with diabetic macular edema (swelling in the back of the eye due to diabetes). The goal is to see if it can improve vision and reduce swelling.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 1 or type 2 diabetes with stable blood sugar control (HbA1c 10% or lower)
- Your vision loss is mainly from diabetic macular edema in the study eye
- Your best corrected vision in the study eye is between 20/40 and 20/320 (on the eye chart)
- The center of your retina is at least 300 microns thick on an eye imaging test (OCT)
- You have not had certain eye surgeries (like vitrectomy or glaucoma filter) in the study eye
- You have not received certain eye medications (steroids or anti-VEGF injections) within 3-6 months before starting the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two injectable medicines (BAT5906 and Lucentis) to treat diabetic macular edema—swelling in the back of the eye that blurs vision. Both drugs block a protein that causes abnormal blood vessel leakage, and this trial will show which works better.
This trial tests an investigational drug called CU06-1004 for people with diabetic macular edema (swelling in the center of the retina caused by diabetes). It aims to see if the drug can improve vision and reduce swelling.
This trial compares a new treatment (EYP-1901, given as an injection) to a standard injection (aflibercept) for people with diabetic macular edema. It aims to see which works better at reducing swelling and improving vision.
This phase 3 trial tests a new long-acting injection (EYP-1901) against a standard one (aflibercept) for people with diabetic macular edema. Both treatments are given as eye injections, and the goal is to see if the new drug works as well and may require fewer injections.
This trial tests whether a substance called tauroursodeoxycholate (TUDCA) or a traditional Chinese medicine can help reduce swelling in the back of the eye caused by diabetes. It is for people with diabetic retinopathy and diabetic macular edema who have not had recent eye surgeries or changes in blood sugar or blood pressure control.
This trial tests a gene therapy for diabetic macular edema (DME), a condition where fluid builds up in the central part of the eye's retina. It aims to improve vision and reduce the need for frequent eye injections.
Hear when a new Diabetic Macular Edema (DME) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.